Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2005
Date of Filing: July 27, 2005
Oncolytics is a development-stage biotechnology company focused on REOLYSIN, a proprietary formulation of the human reovirus intended as a cancer therapeutic. The company has not been profitable since its inception and expects to continue incurring substantial losses until its product becomes commercially viable.
Key Financial Metrics
| Metric | Q2 2005 (3 Months) | Q2 2004 (3 Months) | YTD 2005 (6 Months) | YTD 2004 (6 Months) |
|---|---|---|---|---|
| Revenue | $168,000 | $183,000 | $412,637 | $300,815 |
| Net Loss | ($2,954,720) | ($3,191,888) | ($5,331,769) | ($5,868,124) |
| Loss Per Share (Basic/Diluted) | $0.09 | $0.11 | $0.16 | $0.21 |
| Cash & Cash Equivalents | $31,974,580 | $25,522,000 | $31,974,580 | $33,919,223 (Dec 31, 2004) |
| Working Capital | $31,254,471 | N/A | $31,254,471 | $33,268,097 (Dec 31, 2004) |
| Long-Term Debt | $150,000 | $150,000 | $150,000 | $150,000 |
Note: Revenue consists primarily of interest income and income from short-term investments. The company has no operating revenue from product sales.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately $237,000 in Q2 2005 compared to Q2 2004. This improvement was driven primarily by a significant reduction in stock-based compensation expenses ($8,404 in 2005 vs. $734,670 in 2004).
- Increased R&D Spend: Research and Development expenses increased to $2,050,707 in Q2 2005 from $1,495,934 in Q2 2004. This was due to higher manufacturing costs ($949,169 vs. $446,504) and clinical trial expenses ($549,505 vs. $123,150) as the company expanded its trial portfolio.
- Operating Expenses: Operating expenses decreased to $769,511 in Q2 2005 from $850,773 in Q2 2004, attributed to lower costs for the annual report and general meeting.
- Cash Position: Cash and cash equivalents decreased by approximately $2 million from year-end 2004 to June 30, 2005, reflecting cash outflows for R&D and operations, partially offset by $3.3 million raised from the exercise of warrants and options.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The company received FDA approval to commence a Phase I systemic administration study in the U.S. and has five ongoing clinical trials (enrolling or approved) across the U.S., Canada, and the U.K.
- Capital Resources: Management anticipates an average cash usage of approximately $1,000,000 per month. Existing capital resources are deemed adequate to fund current plans through 2007.
- Future Funding: If additional capital is required, the company intends to seek funding primarily through the issuance of additional equity.
Risks and Contingencies
- Development Stage Risks: As a development-stage company, there is no assurance that REOLYSIN will prove safe and effective in humans or achieve regulatory approval.
- Capital Market Volatility: The company faces uncertainty in raising additional capital due to volatile market prices for biotechnology securities.
- Forward-Looking Statements: Actual results may differ materially from expectations due to risks related to clinical trial success, regulatory processes, competition, and technology changes.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the ~$1M/month cash burn rate against the current cash balance of ~$32M to confirm the runway through 2007.
- Clinical Trial Milestones: Monitor enrollment progress in the five active clinical trials, specifically the new U.S. Phase I systemic study and the U.K. combination radiation trial.
- Manufacturing Costs: Track product manufacturing expenses, which are expected to increase throughout 2005 to supply expanding clinical programs.
- Equity Dilution: Review the impact of potential future equity issuances, given the company's reliance on equity markets for funding and the existing 32.9M shares outstanding (38M fully diluted).
- Patent Portfolio: Confirm the status of the second European Patent for the "Method of Producing Infectious Reovirus" announced subsequent to the quarter end.